drugset / Trial / NCT03200821
An Open Label Study to Evaluate G17DT Compared to Gemcitabine
RandomizedParallel-groupOpen-labelTreatment
Summary
In this study 250 µg of G17DT was administered at Weeks 0, 2 and 6 in order to demonstrate non inferiority compared to gemcitabine in prolonging survival in advanced pancreatic cancer.
Timeline
- Start
- 2000-08-14
- Primary completion
- 2001-09-24
- Completion
- 2002-09-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | G17DT Immunogen | Vaccine | 250 ug | Intramuscular |
| Comparator | Gemcitabine | Small molecule | 1000 ug/m2 | Intravenous |